Population-based molecular screening for lynch syndrome: Implications for personalized medicine

Journal of Clinical Oncology

Volumn 31, Issue 20, 2013, Pages 2554-2562

  Ward, Robyn L ^a   Hicks, Sian ^a   Hawkins, Nicholas J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ENZYME; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MUTL PROTEIN HOMOLOG 1; PROTEIN MSH2; PROTEIN MSH6; BRAF PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER INCIDENCE; CANCER PATIENT; CANCER SCREENING; CARCINOGENESIS; CLINICAL DECISION MAKING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; PATIENT DECISION MAKING; PATIENT REFERRAL; PERSONALIZED MEDICINE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEPLETION; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; AUSTRALIA; COLORECTAL TUMOR; COMPARATIVE STUDY; CONFIDENCE INTERVAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; INCIDENCE; METHODOLOGY; MORTALITY; MUTATION; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRALIA; BIOPSY, NEEDLE; COHORT STUDIES; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOGISTIC MODELS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84883873822     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.8454     Document Type: Article

References (36)

1. Bellcross CA, Bedrosian SR, Daniels E, et al: Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: Summary of a public health/clinical collaborative meeting. Genet Med 14:152-162, 2012
2. South CD, Yearsley M, Martin E, et al: Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. Genet Med 11:812-817, 2009
3. Samowitz WS, Curtin K, Lin HH, et al: The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 121:830-838, 2001
4. Hampel H, Frankel WL, Martin E, et al: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352: 1851-1860, 2005
5. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al: Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 61: 865-872, 2012
6. Lynch HT, Lynch PM, Lanspa SJ, et al: Review of the Lynch syndrome: History, molecular genetics, screening, differential diagnosis, and med-icolegal ramifications. Clin Genet 76:1-18, 2009
7. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, et al: Ten years after mutation testing for Lynch syndrome: Cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793-4797, 2009
8. Hampel H, Frankel WL, Martin E, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26: 5783-5788, 2008
9. Berg AO, Armstrong K, Botkin J, et al: Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35-41, 2009
10. Jensen LH, Lindebjerg J, Kølvraa S, et al: Molecular screening for Lynch syndrome: From bench to bedside. J Clin Oncol 27:e224, 2009
11. Vasen HFA, Möslein G, Alonso A, et al: Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 9:109-115, 2010
12. Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-269, 2006
13. Mvundura M, Grosse SD, Hampel H, et al: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12:93-104, 2010
14. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part I—The utility of immunohistochemistry. J Mol Diagn 10:293-300, 2008
15. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875, 1998
16. de la Chapelle A, Palomaki G, Hampel H: Identifying Lynch syndrome. Int J Cancer 125:1492-1493, 2009
17. Deng G, Bell I, Crawley S, et al: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191-195, 2004
18. Jahn S, Minai-Pour MB, Speicher MR, et al: Comprehensive screening for Lynch syndrome: Who can be the driving force in daily clinical practice? J Clin Oncol 27:2292, 2009
19. Hall MJ: Counterpoint: Implementing population genetic screening for Lynch syndrome among newly diagnosed colorectal cancer patients—Will the ends justify the means? J Natl Compr Canc Netw 8:606-611, 2010
20. Cancer Institute NSW: Cancer in New South Wales: Incidence and mortality—Online statistics module. http://www.cancerinstitute.org.au/data-andstatistics/cancer-statistics/online-statistics-module
21. Edge SB, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer-Verlag, 2009
22. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998
23. Ward RL, Turner J, Williams R, et al: Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 207:377-384, 2005
24. Packham D, Ward RL, Ap Lin V, et al: Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn Mol Pathol 18:62-71, 2009
25. Institute of Medical Genetics Cardiff: Human Gene Mutation Database. http://www.hgmd.cf.ac.uk/ac/index.php
26. Woods MO, Williams P, Careen A, et al: A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 28: 669-673, 2007
27. International Society for Gastrointestinal Hereditary Tumours: InSiGHT Colon Cancer Gene Variant Database. http://www.insight-group.org/mutations/
28. Memorial University of Newfoundland: MMR Genes Variant Database. http://www.med.mun.ca/mmrvariants/
29. Hitchins MP, Rapkins RW, Kwok CT, et al: Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5UTR. Cancer Cell 20:200-213, 2011
30. Graubard BI, Korn EL: Predictive margins with survey data. Biometrics 55:652-659, 1999
31. Pinol V, Castells A, Andreu M, et al: Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986-1994, 2005
32. Hayden EC: Sequencing set to alter clinical landscape. Nature 482:288, 2012
33. Palomaki GE, McClain MR, Melillo S, et al: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11:42-65, 2009
34. Sjursen W, Haukanes BI, Grindedal EM, et al: Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet 47:579-585, 2010
35. Bessa X, Ballesté B, Andreu M, et al: A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6:206-214, 2008
36. Wish TA, Hyde AJ, Parfrey PS, et al: Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: A population-based study. Cancer Epide-miol Biomarkers Prev 19:1831-1839, 2010